A famous virologist reminded that Molnupiravir may be "Pandora's box"

However, a well-known virology expert said that the use of Molnupiravir does more harm than good to people at high risk of serious diseases, and may release a new and more deadly variant of SARS-CoV-2

Last month, officials from Merck and Ridgeback announced the results of a clinical trial that found that the drug was given to COVID-19 patients in the early stages of the diseaseReduce the risk of hospitalization and death by 50%

Said: "While we are deeply concerned about new variants, you are putting a drug into the cycle.

If COVID-19 patients feel better after a few days and stop taking Molnupiravir, Haseltine is worried that the mutant strain of the virus will survive and may spread to other people

Katzourakis said: "I disagree with this.

For example, two years ago, Vanderbilt University virologist Mark Denison and his colleagues repeatedly emphasizedExposure of the coronavirus to a sublethal dose of a drug called EIDD-1931Check for the emergence of drug-resistant viruses

Denison said: "If I remove anything from our study, that is, if the virus attempts to adapt, for example by resistance to Molnupiravir, and it will continue to produce harmful mutations

Hazuda said that among the patients who completed the 5-day course of treatment, “we did not see any infectious virus”, let alone mutations

Katzourakis said: "There is no shortage of virus mutations

Friday’s news report, another antiviral drug from PfizerHighly effective anti-SARS-CoV-2A method to prevent drug resistance is proposed: the combined use of two drugs, which is the same multi-functional strategy as the treatment of HIV and other infections

(From the Internet, for reference only)